Samsung Organoids
With advanced expertise and technology, Samsung Biologics accelerates the early discovery and evaluation of new drug candidates with Samsung Organoids.
Samsung Organoids pave the way for quality-first, end-to-end support for your drug development journey with patient-derived organoids (PDOs). As a trusted CDMO partner, we expedite your drug development process and ensure the timely delivery of life-saving therapies.
Patient-Derived Tumor Organoids for Precision Screening
Patient-derived organoids are 3D tumor models that mirror individual cancers. We offer precision drug screening to help you identify effective compounds with higher clinical relevance, covering colorectal, lung, liver, gastric, and breast cancers.
- Patient
- Cancer Tissue
- Samsung Organoids
- Organoid Biobank
Service Offerings
We continuously commit to serving your evolving needs from an early stage. With extensive data and detailed analysis from early discovery to clinical trials, we effectively address key challenges in drug discovery to advance your journey toward clinical success.
-
Research / Early DiscoveryEvaluate efficacy to support drug evaluation and
lead selection, enhancing clinical success rates -
Late Discovery /
CDO -
Clinical
Manufacturing -
Commercial
Manufacturing
-
-
Target Discovery
-
- Therapeutic target validation
- Disease-relevant organoids
model development
-
-
-
Lead Selection
-
- Lead identification
- Efficacy examination
-
-
-
Preclinical
Development -
- Biomarker identification
- Drug selection support based
on multi-modal data
-
-
-
Clinical Trial
-
- Indication expansion
- Patient stratification for clinical trial
-
Features
Samsung Organoids accelerate your drug development journey with precise predictive models and reliable data.
-
-
Rapid, Bespoke
Organoid Support - Accelerated market entry with organoids tailored to your therapeutic target and development stage
-
Rapid, Bespoke
-
-
Comprehensive Analysis
and Screening - Deep biological insights with multi-modal tumor data, including WES, RNA-seq, and matched patient profiles
-
Comprehensive Analysis
-
-
Reproducible,
High-Quality Data - Quality-assured organoids backed by robust, validated datasets to support confident decision-making in drug screening
-
Reproducible,
Related Content